Shares of Sientra Inc (NASDAQ:SIEN) have earned an average rating of “Buy” from the twelve research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $15.75.
SIEN has been the topic of a number of recent analyst reports. William Blair upgraded shares of Sientra from a “market perform” rating to an “outperform” rating in a report on Tuesday, November 5th. Canaccord Genuity set a $13.00 price objective on shares of Sientra and gave the stock a “buy” rating in a report on Tuesday, September 24th. Zacks Investment Research downgraded shares of Sientra from a “buy” rating to a “sell” rating in a research report on Thursday, January 9th. ValuEngine raised shares of Sientra from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Finally, BidaskClub raised shares of Sientra from a “sell” rating to a “hold” rating in a research report on Thursday, October 10th.
SIEN stock traded down $0.43 during trading on Friday, reaching $7.65. The stock had a trading volume of 427,508 shares, compared to its average volume of 416,383. Sientra has a 1-year low of $4.78 and a 1-year high of $13.47. The company has a current ratio of 2.80, a quick ratio of 2.32 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $399.81 million, a P/E ratio of -2.24 and a beta of 0.37. The firm has a fifty day moving average price of $8.52 and a 200 day moving average price of $7.11.
Sientra (NASDAQ:SIEN) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.02. Sientra had a negative net margin of 143.76% and a negative return on equity of 122.95%. The firm had revenue of $22.41 million for the quarter, compared to analyst estimates of $20.05 million. During the same quarter in the previous year, the business posted ($0.72) EPS. The firm’s revenue was up 32.8% compared to the same quarter last year. Sell-side analysts predict that Sientra will post -1.94 EPS for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd increased its position in shares of Sientra by 282.5% in the 2nd quarter. Point72 Hong Kong Ltd now owns 3,997 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 2,952 shares during the last quarter. NumerixS Investment Technologies Inc bought a new stake in shares of Sientra in the 2nd quarter worth about $59,000. Private Advisor Group LLC bought a new stake in shares of Sientra in the 2nd quarter worth about $62,000. Commonwealth Equity Services LLC bought a new stake in shares of Sientra in the 3rd quarter worth about $84,000. Finally, Voya Investment Management LLC bought a new stake in shares of Sientra in the 3rd quarter worth about $85,000. 89.71% of the stock is owned by institutional investors.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Featured Story: Gross Domestic Product (GDP)
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.